Level of DNA-fragmentation Before and After Antioxidant-based Therapies in Male Infertility
Launched by JANNA PAPE · Sep 17, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into how antioxidants and lifestyle changes can affect male infertility. Specifically, the study will measure DNA damage in sperm, which can be caused by a condition called oxidative stress. By checking the DNA fragmentation index (DFI), researchers hope to see how effective antioxidant treatments might be in reducing this damage and improving fertility.
To participate in this trial, men who are facing infertility issues and are eager to start treatment with their partner may be eligible. Participants must be willing to join the study and provide written consent. However, those who have certain health conditions, take specific medications, or have been exposed to harmful substances will not be able to take part. As the study is not yet recruiting, participants can expect more information about the trial procedures and what to expect once it begins.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Willing to participate
- • Written consent
- • Men with infertility problems who want to start an infertility treatment with their partner
- Exclusion Criteria:
- • No measurement of DNA fragmentation possible
- • Intake of prescribed medications
- • Exposure to toxins
- • Chronic diseases
About Janna Pape
Janna Pape is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous methodologies. With a focus on ethical practices and regulatory compliance, Janna Pape collaborates with healthcare professionals and research institutions to facilitate the development of novel therapies across various therapeutic areas. The organization emphasizes transparency and integrity in all its operations, ensuring that the highest standards of quality are maintained throughout the clinical trial process. Through strategic partnerships and a patient-centric approach, Janna Pape aims to contribute significantly to the advancement of science and the betterment of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Michael von Wolff, Prof
Study Chair
Universitätsklinik fur Frauenheilkunde, Inselspital Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported